Karyopharm Therapeutics (KPTI)
(Delayed Data from NSDQ)
$0.89 USD
+0.01 (0.73%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $0.88 -0.01 (-0.83%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.89 USD
+0.01 (0.73%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $0.88 -0.01 (-0.83%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Zacks News
Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -1.47% and 45.86%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Karyopharm Therapeutics (KPTI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Karyopharm Therapeutics (KPTI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Karyopharm Therapeutics (KPTI) stock based on the movements in the options market lately.
Analysts Estimate Karyopharm Therapeutics (KPTI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -10.00% and -12.23%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -1.72% and -0.81%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Karyopharm's (KPTI) Xpovio Gets FDA Nod for Second-Line Myeloma
by Zacks Equity Research
Karyopharm (KPTI) gets FDA approval for label expansion of its marketed drug, Xpovio, in combination with Takeda's Velcade and dexamethasone for treating multiple myeloma in second-line setting.
Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 0.00% and -0.08%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Karyopharm Therapeutics (KPTI) Q3 Earnings Expected to Decline
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Karyopharm Therapeutics (KPTI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Karyopharm Therapeutics (KPTI) stock based on the movements in the options market lately.
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -10.53% and 19.57%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Karyopharm's Xpovio Gets FDA Accelerated Approval for DLBCL
by Zacks Equity Research
Karyopharm (KPTI) gets FDA approval for label expansion of its marketed drug, Xpovio, in relapsed or refractory diffuse large B-cell lymphoma.
Karyopharm Starts Dosing in Selinexor Study for Glioblastoma
by Zacks Equity Research
Karyopharm (KPTI) commences a phase I/II study evaluating Xpovio (selinexor) in combination with standard-of-care therapy in patients with newly-diagnosed or recurrent glioblastoma.
Are Options Traders Betting on a Big Move in Karyopharm Therapeutics (KPTI) Stock?
by Zacks Equity Research
Investors need to pay close attention to Karyopharm Therapeutics (KPTI) stock based on the movements in the options market lately.
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -11.43% and -15.99%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Karyopharm (KPTI) Might Surprise This Earnings Season
by Zacks Equity Research
Karyopharm (KPTI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Top Ranked Momentum Stocks to Buy for April 30th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, April 30th.
What Makes Karyopharm Therapeutics (KPTI) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Karyopharm Therapeutics (KPTI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Karyopharm Starts Dosing With Selinexor for Coronavirus Infection
by Zacks Equity Research
Karyopharm (KPTI) doses the first patient in a phase II study evaluating the low dose of its drug Xpovio (selinexor) to treat hospitalized patients with severe COVID-19 infection. Shares up.
Karyopharm (KPTI): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Karyopharm (KPTI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well
Company News for Mar 3, 2020
by Zacks Equity Research
Companies in the news are: FTSV, MINI, KPTI ATEC
Do Options Traders Know Something About Karyopharm (KPTI) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Karyopharm (KPTI) stock based on the movements in the options market lately.
What's in Store for AstraZeneca (AZN) This Earnings Season?
by Zacks Equity Research
AstraZeneca's (AZN) fourth-quarter results are expected to reflect the impact of new drug sales.
What's in Store for Acorda (ACOR) This Earnings Season?
by Zacks Equity Research
During Acorda's (ACOR) Q4 earnings call, investor focus will be on the sales uptake of its newly-launched Parkinson's disease drug Inbrija.